Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02998476
Title A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Incyte Corporation
Indications

diffuse large B-cell lymphoma

Therapies

Parsaclisib

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | CAN | BEL


No variant requirements are available.